€ 0.13
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Medigene AG is presently engaged in the liquidation of its residual assets. Its prior endeavors centered on advancing T-cell therapies designed to combat cancer. The company was founded in 1994 and maintains its principal office in Munich, Germany.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive
Data is available to registered users only